Loading organizations...
§ Private Profile · 1611 Telegraph Ave Ste 500, Oakland, California, 94612, United States
Genomics software with AI-driven tools to analyze genomes, exomes, & gene panels for clinical precision medicine.
Based in Oakland, California, Fabric Genomics (formerly Omicia) develops AI-driven genomics software to process and analyze whole genomes, exomes, and gene panels for precision medicine applications. The company licenses its algorithmic tools to commercial laboratories and hospital core labs, reaching a user base of over 1,000 academic institutions and clinical facilities worldwide. Its proprietary software enables genetic analysis in under one hour while achieving causative yields of up to 54 percent. Fabric Genomics raised $23 million in Series B funding in 2016 and established strategic partnerships with entities like Broad Clinical Labs, while maintaining historical ties to Illumina through its leadership. In 2025, the business was acquired by genetic testing company GeneDx to operate as an independent subsidiary. The enterprise was founded in 2009 by Martin Reese, Edward Kiruluta, John Stuelpnagel, and Paul Billings.
Fabric Genomics (formerly Omicia) has raised $30.0M across 2 funding rounds.
Fabric Genomics (formerly Omicia) has raised $30.0M in total across 2 funding rounds.
Fabric Genomics (formerly Omicia) develops AI-driven clinical decision support software for genomic data analysis, enabling accurate diagnoses in hereditary diseases, oncology, and rare disorders. Its Enterprise Platform processes whole genomes, exomes, and gene panels for commercial clinical labs, hospital systems, country-sequencing programs, and research institutions, delivering high diagnostic yields (up to 54% causative candidates) and rapid turnaround (under 1 hour for whole genomes).[1][2][5] The company serves leading organizations like Cincinnati Children’s, InterMountain, and Rady Children’s Institute, solving the challenge of scalable, precise genomic interpretation to advance precision medicine.[2][5] Acquired by GeneDx Holdings in April 2025 for $33M–$84M, Fabric maintains operational independence while gaining commercial backing, with total funding raised of $31.43M prior to acquisition.[1][2]
Fabric Genomics was founded in 2009 in Oakland, California, by Martin Reese, Ph.D. (co-founder, President, and CEO), Edward Kiruluta (co-founder), John Stuelpnagel, and Paul Billings, M.D., Ph.D. (co-founder and Acting Chief Medical Officer), with a vision to generate clinical insights from genomic analysis using AI and machine learning.[1][2][3][5][6] Initially focused on research tools, the company pivoted to clinical applications after raising an $8.3M Series A in December 2013.[2] Pivotal moments included selection for the UK's 100,000 Genomes Project in 2015, a $23M Series B in 2016, oncology expansion in 2017, and the launch of its scalable AI variant classification engine, ACE, in 2019—building early traction with over 1,000 academic and clinical users worldwide.[1][2]
Fabric Genomics rides the genomics and precision medicine wave, fueled by falling sequencing costs, AI advancements, and demand for rapid diagnostics in NICUs, oncology, and global newborn screening programs.[1][2][5] Timing aligns with post-2020 NGS adoption surges and regulatory pushes like Genomics England, positioning Fabric to enable large-scale programs amid a 2.8 million U.S. children with rare disorders.[1][4] Market forces favoring it include AI's role in variant interpretation bottlenecks and partnerships (e.g., Oxford Nanopore for pediatric WGS), influencing the ecosystem by standardizing AI-driven analysis for 1,000+ institutions and accelerating decentralized genomic testing.[2][4][5]
As a GeneDx subsidiary, Fabric will likely expand neonatal testing, gNBS worldwide, and oncology/trial matching, leveraging parental resources for global scale.[1] Trends like AI-enhanced NGS, regulatory harmonization, and population screening will propel growth, evolving its influence from software provider to precision medicine enabler. This builds on its trailblazing foundation, ensuring genomic insights drive standard care.[2][5]
Fabric Genomics (formerly Omicia) has raised $30.0M across 2 funding rounds. Most recently, it raised $23.0M Series B in June 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2016 | $23M Series B | — | ARTIS Ventures, BoxGroup, Craft Ventures, Founder Collective, Founders Fund, Innovation Endeavors, Khosla Ventures, Offline Ventures, RED Swan Ventures, Seven Seven SIX, Slow Ventures, Thrive Capital, Bobby Goodlatte, Charlie Cheever, Greg Maffei, Oliver Jung, Acadia Woods, Buchanan Investments, LDV Partners, Jiang Zhang, Roche, TAL Heppenstall | Announced |
| Jan 1, 2014 | $7M Series A | — | ARTIS Ventures, BoxGroup, Craft Ventures, Founder Collective, Founders Fund, Innovation Endeavors, Khosla Ventures, Offline Ventures, RED Swan Ventures, Seven Seven SIX, Slow Ventures, Thrive Capital, Bobby Goodlatte, Charlie Cheever, Greg Maffei, Oliver Jung, Acadia Woods, William Gerber, TAD Buchanan, Casdin Capital | Announced |
Fabric Genomics (formerly Omicia) has raised $30.0M in total across 2 funding rounds.
Fabric Genomics (formerly Omicia)'s investors include Artis Ventures (AV), BoxGroup, Craft Ventures, Founder Collective, Founders Fund, Innovation Endeavors, Khosla Ventures, Offline Ventures, Red Swan Ventures, Seven Seven Six, Slow Ventures, Thrive Capital.